BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

467 related articles for article (PubMed ID: 24519384)

  • 21. Effect of ursodeoxycholic acid on bile acid profiles and intestinal detoxification machinery in primary biliary cirrhosis and health.
    Dilger K; Hohenester S; Winkler-Budenhofer U; Bastiaansen BA; Schaap FG; Rust C; Beuers U
    J Hepatol; 2012 Jul; 57(1):133-40. PubMed ID: 22414767
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ursodeoxycholic acid administration in patients with cholestasis of pregnancy: effects on primary bile acids in babies and mothers.
    Mazzella G; Rizzo N; Azzaroli F; Simoni P; Bovicelli L; Miracolo A; Simonazzi G; Colecchia A; Nigro G; Mwangemi C; Festi D; Roda E
    Hepatology; 2001 Mar; 33(3):504-8. PubMed ID: 11230728
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pregnancy course in patients with intrahepatic cholestasis of pregnancy treated with very low doses of ursodeoxycholic acid.
    Grymowicz M; Czajkowski K; Smolarczyk R
    Scand J Gastroenterol; 2016 Jan; 51(1):78-85. PubMed ID: 26152830
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Relationship between biliary and serum bile acids and response to ursodeoxycholic acid in patients with primary biliary cirrhosis.
    Lindor KD; Lacerda MA; Jorgensen RA; DeSotel CK; Batta AK; Salen G; Dickson ER; Rossi SS; Hofmann AF
    Am J Gastroenterol; 1998 Sep; 93(9):1498-504. PubMed ID: 9732932
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Impact of inflammatory bowel disease and ursodeoxycholic acid therapy on small-duct primary sclerosing cholangitis.
    Charatcharoenwitthaya P; Angulo P; Enders FB; Lindor KD
    Hepatology; 2008 Jan; 47(1):133-42. PubMed ID: 17992695
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Bezafibrate treatment: a new medical approach for PBC patients?
    Kanda T; Yokosuka O; Imazeki F; Saisho H
    J Gastroenterol; 2003; 38(6):573-8. PubMed ID: 12825134
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Effect of S-adenosyl-L-methionine on liver biochemistry and quality of life in patients with primary biliary cholangitis treated with ursodeoxycholic acid. A prospective, open label pilot study.
    Wunsch E; Raszeja-Wyszomirska J; Barbier O; Milkiewicz M; Krawczyk M; Milkiewicz P
    J Gastrointestin Liver Dis; 2018 Sep; 27(3):273-279. PubMed ID: 30240471
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Ursodeoxycholic acid in primary sclerosing cholangitis: if withdrawal is bad, then administration is good (right?).
    Tabibian JH; Lindor KD
    Hepatology; 2014 Sep; 60(3):785-8. PubMed ID: 24752961
    [No Abstract]   [Full Text] [Related]  

  • 29. High-dose ursodeoxycholic acid increases risk of adverse outcomes in patients with early stage primary sclerosing cholangitis.
    Imam MH; Sinakos E; Gossard AA; Kowdley KV; Luketic VA; Edwyn Harrison M; McCashland T; Befeler AS; Harnois D; Jorgensen R; Petz J; Keach J; DeCook AC; Enders F; Lindor KD
    Aliment Pharmacol Ther; 2011 Nov; 34(10):1185-92. PubMed ID: 21957881
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Effect of ursodeoxycholic acid on the kinetics of cholic acid and chenodeoxycholic acid in patients with primary sclerosing cholangitis.
    Rudolph G; Endele R; Senn M; Stiehl A
    Hepatology; 1993 Jun; 17(6):1028-32. PubMed ID: 8514251
    [TBL] [Abstract][Full Text] [Related]  

  • 31. A randomized trial in primary biliary cirrhosis comparing ursodeoxycholic acid in daily doses of either 10 mg/kg or 20 mg/kg. Dutch Multicentre PBC Study Group.
    Van Hoogstraten HJ; De Smet MB; Renooij W; Breed JG; Engels LG; Den Ouden-Muller JW; Rijk MC; Smit AM; Zwertbroek R; Hop WC; van Berge Henegouwen GP; Schalm SW; van Buuren HR
    Aliment Pharmacol Ther; 1998 Oct; 12(10):965-71. PubMed ID: 9798800
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A Triple Blinded, Randomized, Placebo-Controlled Clinical Trial to Evaluate the Efficacy and Safety of Oral Vancomycin in Primary Sclerosing Cholangitis: a Pilot Study.
    Rahimpour S; Nasiri-Toosi M; Khalili H; Ebrahimi-Daryani N; Nouri-Taromlou MK; Azizi Z
    J Gastrointestin Liver Dis; 2016 Dec; 25(4):457-464. PubMed ID: 27981301
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Medical treatment of primary biliary cirrhosis and primary sclerosing cholangitis.
    Holtmeier J; Leuschner U
    Digestion; 2001; 64(3):137-50. PubMed ID: 11786661
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [-Therapy with ursodeoxycholic acid in primary biliary cirrhosis in pregnancy-].
    Rudi J; Schönig T; Stremmel W
    Z Gastroenterol; 1996 Mar; 34(3):188-91. PubMed ID: 8650973
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Ursodeoxycholic acid in the treatment of intrahepatic cholestasis of pregnancy. A 12-year experience.
    Zapata R; Sandoval L; Palma J; Hernández I; Ribalta J; Reyes H; Sedano M; Tohá D; Silva JJ
    Liver Int; 2005 Jun; 25(3):548-54. PubMed ID: 15910492
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Characteristics and clinical course of primary sclerosing cholangitis in France: a prospective cohort study.
    Garioud A; Seksik P; Chrétien Y; Corphechot C; Poupon R; Poupon RE; Chazouillères O
    Eur J Gastroenterol Hepatol; 2010 Jul; 22(7):842-7. PubMed ID: 19779305
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Prolonged fibroblast growth factor 19 response in patients with primary sclerosing cholangitis after an oral chenodeoxycholic acid challenge.
    Zweers SJ; de Vries EM; Lenicek M; Tolenaars D; de Waart DR; Koelfat KV; Groen AK; Olde Damink SW; Beuers U; Ponsioen C; Jansen PL; Schaap FG
    Hepatol Int; 2017 Jan; 11(1):132-140. PubMed ID: 27696157
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Treatment of primary sclerosing cholangitis with low-dose ursodeoxycholic acid: results of a retrospective Italian multicentre survey.
    Okolicsanyi L; Groppo M; Floreani A; Morselli-Labate AM; Rusticali AG; Battocchia A; Colombo M; Galatola G; Gasbarrini G; Podda M; Ricci G; Rosina F; Zuin M
    Dig Liver Dis; 2003 May; 35(5):325-31. PubMed ID: 12846404
    [TBL] [Abstract][Full Text] [Related]  

  • 39. [Treatment of cholestatic liver diseases with ursodeoxycholic acid].
    Boberg KM; Schrumpf E
    Tidsskr Nor Laegeforen; 1997 Sep; 117(23):3370-3. PubMed ID: 9411890
    [TBL] [Abstract][Full Text] [Related]  

  • 40. High-dose ursodeoxycholic acid for the treatment of primary sclerosing cholangitis.
    Smith T; Befeler AS
    Curr Gastroenterol Rep; 2007 Mar; 9(1):54-9. PubMed ID: 17335678
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 24.